First demonstration of universal cancer vaccine
New data shows 27% improved survival in the NIPU trial.
Statsbudsjettet 2024
Her er de viktigste sakene i Statsbudsjettet 2024 for Oslo Cancer Clusters medlemmer.
SurViva joins Oslo Cancer Cluster
SurViva is a Norwegian consultancy providing quality guidance for life science companies.
New research on genetic risk and breast cancer
New Norwegian research in polygenic risk score
A roadmap for the health industry
What is the government’s ambition for the health industry?
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway. It is no longer a question of if but when personalised medicine will be a reality for all cancer patients in Norway. This was a key message in a recent meeting arranged by the public-private consortium CONNECT during Arendalsuka, where the […]